Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventracor eyes 2007 EU LVAD (left ventricular assist device) nod:

This article was originally published in Clinica

Executive Summary

Ventracor believes it is on course to CE-marking for sale in Europe early next year its VentrAssist heart pump, following positive data from its bridge-to-transplant clinical trial. The left ventricular assist device (LVAD) showed an 83% success rate - significantly better than earlier published results of first generation devices - and the adverse event rate was in line with expectations, said the company. The results were presented at the European Association of Cardiothoracic Surgeons' annual meeting in Sweden this month. VentrAssist is a third generation centrifugal implantable blood pump designed for long-term use in patients with advanced heart failure. The pump has no wearing parts and is lightweight and small, enabling it to be used in both children and adults.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel